<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01795846</url>
  </required_header>
  <id_info>
    <org_study_id>12L3330001</org_study_id>
    <nct_id>NCT01795846</nct_id>
  </id_info>
  <brief_title>Evaluation of Immunological Changes and Clinical Efficacy of Specific Immunotherapy With Der p House Dust Mite Allergen in Polysensitized and Monosensitized Patients With Allergic Rhinitis and/or Asthma.</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ankara University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ankara University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The incidence of allergic rhinitis and asthma is increasing in throughout the world as well
      as our country. Allergen-specific immunotherapy has been in use for almost 100 years. Since
      then, it is recommended for the management of Immunoglobulin E (IgE)-mediated allergic
      diseases as the only immune modulator therapeutic tool. It is well documented that allergen
      immunotherapy performed using single allergen is efficacious in monosensitized patients.
      Hence, polysensitization is much more prevalent than monosensitization in patients with
      respiratory allergy. On the other hand, polysensitization may have a paramount relevance in
      clinical practice; for example, many allergists have doubts in choosing the allergen extract
      for allergen specific immunotherapy. In this regard, the evaluation of immunotherapy efficacy
      in polysensitized patients still represents an unanswered question and there are very few
      studies on this issue. However, most clinical trials of allergen immunotherapy have been
      performed with multiple different allergen extracts using sublingual route. To the best of
      our knowledge, no common single-allergen (house dust mite Dermatophagoides pteronyssinus, Der
      p) subcutaneous immunotherapy trials have been specifically designed to compare efficacy in
      monosensitized and polysensitized patients. Furthermore, few studies have demonstrated that
      monosensitized and polysensitized patients appear to differ in terms of their immune
      reactivity. But, it is unknown whether single-allergen immunotherapy protocol elicit distinct
      immune responses in monosensitized and polysensitized patients.

      The aim of this study was to investigate the immunological changes and clinical effectiveness
      of most relevant single-allergen immunotherapy in patients with allergic rhinitis and/or
      asthma. The study population will included 40 adult patients with moderate/severe perennial
      allergic rhinitis and mild/moderate asthma who were monosensitized to house dust mites or
      sensitized to at least 2 different allergens including house dust mites. No patient will
      previously had been performed allergen immunotherapy. The study plan is prospective,
      randomized, double-blind, placebo-controlled. Both groups will first received placebo
      injections for 3 months, and followed by a cluster immunotherapy schedule. After the
      maintenance dose will be reached within 6 weeks, injections will be received at monthly
      intervals. Standardized depot preparations of Der p extract (Alutard Standard Quality SQ,
      ALK-Abello (Company Name), Madrid, Spain ) were administered by means of subcutaneous
      injection. All eligible patients will underwent 8 weeks run-in period to evaluate their
      baseline clinical status based on history of allergy, symptom and medication usage for
      rhinitis and asthma, skin prick testing, pulmonary function tests and methacholine
      bronchoprovocation tests. According to the sensitizations, patients will be divided to 2
      parallel groups either as polysensitized or monosensitized. Afterwards, both patient groups
      will be followed by symptom and medication scales, visual analog scores, quality-of-life
      scores for 1 month before placebo and immunotherapy. During this period, total serum IgE,
      specific IgE levels will be measured using the method of UNI-CAP 100 (Phadia, Uppsala,
      Sweden) and repeated after placebo and immunotherapy injections. At baseline, after placebo
      (3 months) and immunotherapy injections (at third months of maintenance period), nasal
      allergen provocation test with Der p extract will applied to the study groups. Peripheral
      whole blood will drawn for the analysis of basophil activation marker CD203c (CD, cell
      differentiation) expression at this three time points. For the clinical assessment, all
      patients will record on diary cards their symptom scores, visual analog scale scores,
      medication usage, quality-of-life measures for rhinitis and asthma. On each clinical visit,
      physical examination and side effects will be collected from diary card data. In conclusion,
      we believe that this study may be help for more understanding of the immune response to
      allergen specific immunotherapy at early stage. On the other hand, if the similar clinical
      improvement is demonstrated between the two groups with common single-allergen (Der p)
      immunotherapy, unnecessary usage of multiple allergens may be prevented as well as
      therapeutic side affects and cost.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Months</target_duration>
  <primary_outcome>
    <measure>Primary outcome is the assessment data from all patients whom will record on diary cards their symptom scores, visual analog scale scores, medication usage, quality-of-life measures for rhinitis and asthma.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary outcome is the significant changes in total serum IgE, specific IgE levels, basophil activation marker CD203c expression, and nasal allergen provocation tests obtained from all patients during the study period.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Measurement of the levels of specific Immunoglobulin G4 (IgG4)blocking antibodies.</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Allergen Immunotherapy, Immunological Mechanisms,Monosensitized,Polysensitized,Clinical Efficacy</condition>
  <arm_group>
    <arm_group_label>monosensitized allergic rhinitis, asthma</arm_group_label>
    <description>adult patients with moderate/severe perennial allergic rhinitis and mild/moderate asthma who were monosensitized to house dust mites</description>
  </arm_group>
  <arm_group>
    <arm_group_label>polysensitized allergic rhinitis, asthma</arm_group_label>
    <description>adult patients with moderate/severe perennial allergic rhinitis and mild/moderate asthma who were monosensitized to house dust mites or sensitized to at least 2 different allergens including house dust mites.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Allergen specific immunotherapy and placebo injections</intervention_name>
    <arm_group_label>monosensitized allergic rhinitis, asthma</arm_group_label>
    <arm_group_label>polysensitized allergic rhinitis, asthma</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will included adult patients with moderate/severe perennial allergic
        rhinitis and mild/moderate asthma who were monosensitized to house dust mites or sensitized
        to at least 2 different allergens including house dust mites. No patient will previously
        had been performed allergen immunotherapy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with moderate or persistent allergic rhinitis with or without mild asthma are
        selected in the study. They have to sensitized to only house dust mites or at least 2
        different allergens including house dust mites.

        Exclusion Criteria:The presence of severe asthma, previously received allergen
        immunotherapy and other contraindications of allergen specific immunotherapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ankara University, Faculty of Medicine</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sadan Soyyigit, M.D.</last_name>
      <phone>0-90-312 595 65 83</phone>
      <email>sadansoyyigit@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Sadan Soyyigit, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <link>
    <url>http://www.aaaai.org</url>
    <description>American Academy of Allergy Asthma Immunology</description>
  </link>
  <results_reference>
    <citation>Calder√≥n MA, Cox L, Casale TB, Moingeon P, Demoly P. Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patients: looking at the published evidence. J Allergy Clin Immunol. 2012 Apr;129(4):929-34. doi: 10.1016/j.jaci.2011.11.019. Epub 2012 Jan 11. Review.</citation>
    <PMID>22244595</PMID>
  </results_reference>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2013</study_first_submitted>
  <study_first_submitted_qc>February 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2013</study_first_posted>
  <last_update_submitted>February 28, 2013</last_update_submitted>
  <last_update_submitted_qc>February 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ankara University</investigator_affiliation>
    <investigator_full_name>Betul Ayse Sin</investigator_full_name>
    <investigator_title>Ankara University, Faculty of Medicine, Dept. of Chest Diseases, Division of Immunology and Allergic Diseases</investigator_title>
  </responsible_party>
  <keyword>allergen specific immunotherapy, house dust mite (Der p), monosensitization, polysensitization, allergic rhinitis, asthma,</keyword>
  <pending_results>
    <submitted>January 19, 2014</submitted>
    <returned>March 5, 2014</returned>
    <submitted>November 12, 2014</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>November 13, 2014</submitted>
    <returned>November 21, 2014</returned>
    <submitted>December 25, 2014</submitted>
    <returned>January 7, 2015</returned>
    <submitted>January 8, 2015</submitted>
    <returned>January 15, 2015</returned>
    <submitted>March 27, 2015</submitted>
    <returned>April 9, 2015</returned>
    <submitted>April 23, 2015</submitted>
    <returned>May 11, 2015</returned>
    <submitted>July 5, 2015</submitted>
    <returned>July 31, 2015</returned>
    <submitted>September 19, 2015</submitted>
    <returned>October 16, 2015</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

